Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.

Filiaciones

Wei, Andrew H.:

Department of Clinical Haematology, The Alfred Hospital, Melbourne, Victoria, Australia

Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia

Sayar, Hamid:

Indiana University Cancer Center, Indianapolis, Indiana, USA

Ravandi, Farhad:

The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Montesinos, Pau:

Hospital Universitario y Politécnico La Fe, Valencia, Spain

Dombret, Herve:

Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France

Selleslag, Dominik:

AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium

Porkka, Kimmo:

HUS Comprehensive Cancer Center, Hematology Research Unit Helsinki and iCAN Digital Precision Cancer Center Medicine Flagship, University of Helsinki, Helsinki, Finland

Skikne, Barry:

University of Kansas Cancer Center, Kansas City, Kansas, USA

Bristol Myers Squibb, Summit, New Jersey, USA

Beach, C. L.:

Bristol Myers Squibb, Summit, New Jersey, USA

Prebet, Thomas:

Bristol Myers Squibb, Summit, New Jersey, USA

Zhang, George:

Bristol Myers Squibb, Summit, New Jersey, USA

Ugidos, Manuel:

BMS Center for Innovation and Translational Research Europe (CITRE, a Bristol-Myers Squibb Company), Seville, Spain

See, Wendy L.:

Bristol Myers Squibb, Summit, New Jersey, USA

Menezes, Daniel:

Bristol Myers Squibb, Summit, New Jersey, USA

Roboz, Gail J.:

Weill Cornell Medicine, New York, New York, USA

New York Presbyterian Hospital, New York, New York, USA